AI Verdict
MATX has stronger fundamentals based on our AI analysis.
MAZE vs MATX Fundamental Comparison
| Metric | MAZE | MATX |
|---|---|---|
| Revenue | $0.0 | $3.3B |
| Net Income | $-131.1M | $444.8M |
| Net Margin | N/A | 13.3% |
| ROE | -36.9% | 16.1% |
| ROA | -33.0% | 9.6% |
| Current Ratio | 15.50x | 0.89x |
| Debt/Equity | 0.00x | 0.13x |
| EPS | $-3.05 | $13.81 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
MAZE vs MATX: Frequently Asked Questions
Is MAZE or MATX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), MATX has stronger fundamentals. MAZE is rated STRONG SELL (92% confidence) while MATX is rated BUY (72% confidence). This is not investment advice.
How does MAZE compare to MATX fundamentally?
Maze Therapeutics, Inc. has ROE of -36.9% vs Matson, Inc.'s 16.1%. Net margins are N/A vs 13.3% respectively.
Which stock pays higher dividends, MAZE or MATX?
MAZE has a dividend yield of N/A or no dividend while MATX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in MAZE or MATX for long term?
For long-term investing, consider that MAZE has STRONG SELL rating with 92% confidence, while MATX has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about MAZE vs MATX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For MAZE vs MATX, the AI consensus favors MATX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.